Journey Medical (DERM) Receivables (2020 - 2025)
Journey Medical (DERM) has disclosed Receivables for 6 consecutive years, with $18.0 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables rose 68.52% year-over-year to $18.0 million, compared with a TTM value of $18.0 million through Sep 2025, up 68.52%, and an annual FY2024 reading of $10.2 million, down 32.79% over the prior year.
- Receivables was $18.0 million for Q3 2025 at Journey Medical, up from $15.6 million in the prior quarter.
- Across five years, Receivables topped out at $31.7 million in Q3 2021 and bottomed at $8.0 million in Q3 2023.
- Average Receivables over 5 years is $19.5 million, with a median of $18.0 million recorded in 2025.
- The sharpest move saw Receivables crashed 72.0% in 2023, then skyrocketed 83.95% in 2025.
- Year by year, Receivables stood at $23.1 million in 2021, then increased by 22.05% to $28.2 million in 2022, then plummeted by 46.04% to $15.2 million in 2023, then plummeted by 32.79% to $10.2 million in 2024, then soared by 75.77% to $18.0 million in 2025.
- Business Quant data shows Receivables for DERM at $18.0 million in Q3 2025, $15.6 million in Q2 2025, and $18.0 million in Q1 2025.